Zhou S H, Rautaharju P M, Prineas R, Neaton J, Crow R, Calhoun H, Furberg C, Cohen J
Cardiac Epidemiology Coordination Research Centre, University of Alberta, Edmonton, Canada.
J Electrocardiol. 1993;26 Suppl:108-13.
Three sets of left ventricular hypertrophy (LVH) criteria were evaluated in terms of their utility for LVH progression and regression incidence estimation. Incidence comparisons were performed with and without taking short-term variability into consideration using electrocardiographic records taken at the baseline and the first annual follow-up examination of 11,969 men, aged 37 to 55 years, at the baseline of the Multiple Risk Factor Intervention Trial. Short-term total technical and biologic variability (95% range) was determined from the records of 104 men invited for a repeat electrocardiographic recording at 2-week or shorter intervals from the first recording. The results indicated that after elimination of the false fraction due to normal variability, the residual incidence estimates are so low that their utility and statistical power in monitoring changes in LVH status is very limited. It is concluded that a redefinition of LVH progression and regression criteria is needed to enhance their utility in clinical trials.
对三组左心室肥厚（LVH）标准在估计LVH进展和逆转发生率方面的效用进行了评估。利用多重危险因素干预试验基线时37至55岁的11969名男性在基线和首次年度随访检查时的心电图记录，在考虑和不考虑短期变异性的情况下进行了发生率比较。从104名被邀请在距首次记录2周或更短间隔重复进行心电图记录的男性记录中确定了短期总技术和生物学变异性（95%范围）。结果表明，在消除正常变异性导致的假阳性部分后，残余发生率估计值非常低，以至于它们在监测LVH状态变化方面的效用和统计效力非常有限。结论是，需要重新定义LVH进展和逆转标准，以提高其在临床试验中的效用。
